-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 8, CorningErry announced that the first patient was given the drug in a key clinical study (research number: SEARCH-01/KN026-203) against HER2 dual-specific antibody KN026 combined PD-L1/CTLA-4 dual-specific monolithic antibody KN046.
SEARCH-01 is an open, phase II. and multi-center clinical study designed to assess the effectiveness, safety and tolerance of KN026 in the treatment of HER2-positive solid tumors.
, led by Professor Shen Lin of Beijing Cancer Hospital, plans to recruit patients with advanced HER2-positive solid tumors in about 40 research centers across the country, including, but not limited to, HER2-positive stomach and gastroesophageal conjoined cancer, breast cancer, esophageal cancer, colorectal cancer, gallbladder cancer and exosperian biletric cancer, ovarian cancer, endometrial cancer, urethra cancer and non-small cell lung cancer.
of the exploratory part of the study were objective mitigation rate (ORR) and mitigation duration (DOR), and the common main endpoint of the key clinical part was total lifetime.
the therapeutic effect of HER2 targets depends on the adaptive immune response of the body, so the associated targets of joint tumor immunity such as PD-1/PD-L1, CTLA-4 can co-enhance the role of the drug anti-tumor.
Current studies have shown that the combined use of HER2 targeted drugs with PD-1 antibodies has shown good results in HER2-positive stomach cancer, with disease control rates, medium progression-free lifetimes and medium total lifetimes far exceeding the historical control values of ToGA studies.
KN026 and KN046 combination therapies achieved initial excellent efficacy and tolerance in an open, multi-center clinical trial for patients with advanced HER2 expression solid tumors who failed standard treatments, and 14 herrings with evaluatable efficacy Among 2 positive patients, objective remission rate (ORR) reached 64.3% and disease control rate (DCR) reached 92.9%, detailed data were recently published at the Annual Meeting of the Society for Cancer Immunotherapy (SITC 2020).
note: There are deletions in the original text
